Antisoma slips back to red ahead of expected Sportingbet deal

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

Cancer drug developer Antisoma saw a return to the red at its half-year report statement, reporting a 30,000 pound loss after tax.

This compares to profits of £424,000 for the full year, reported last October, when the group restructured its activities to become an investment company.

Antisoma made its first major deal as an investment company in the most recent trading period, via an agreement to subscribe to up to £4.0m in new shares proposed for issuance by GVC Holdings. This is in connection with GVC's recommended offer, alongside William Hill, for Sportingbet.

Confirmation on the size of Antisoma's holding in GVC is expected on March 31st.

In the half year to December 31st, Antisoma continued to cut costs, and is now sitting on £12.88m in cash, and short term deposit balances of £9.48m.

Antisoma previously focused on cancer therapy development, but suffered a blow in early 2011 when both its drugs failed in final-stage trials. The group then stopped all its drugs development programmes in an effort to save cash, ahead of the restructuring.

Chairman Michael Bretherton was cautiously optimistic in his outlook for the company, pointing to the troubles in the general economy.

Still, he believes Antisoma's strong cash position and low cost base are encouraging: "This places the company in a good position to exploit opportunities as they emerge in the current volatile economic environment. We will therefore continue to maintain a highly selective investment approach."

JF

Recommended

Ocado faces a “crunch” year – should you buy or avoid?
Share tips

Ocado faces a “crunch” year – should you buy or avoid?

Ocado was one of the big winners from the pandemic as customers moved online. But now it’s struggling, and losses are growing. So, asks Rupert Hargrea…
27 May 2022
What to buy as the tech-stock bull market crashes
Tech stocks

What to buy as the tech-stock bull market crashes

The decade-long bull market in tech stocks has come to a rapid halt. Investors need to distinguish solid stocks from speculative ones rather than just…
27 May 2022
Share tips of the week – 27 May
Share tips

Share tips of the week – 27 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
27 May 2022
Marks & Spencer shares look cheap – should you buy in?
Retail stocks

Marks & Spencer shares look cheap – should you buy in?

Marks & Spencer shares have been a disappointment for investors for two decades. But with the company now on something of a comeback, Rupert Hargreave…
25 May 2022

Most Popular

The world’s hottest housing markets are faltering – is the UK next?
House prices

The world’s hottest housing markets are faltering – is the UK next?

As interest rates rise, house prices in the world’s most overpriced markets are starting to fall. The UK’s turn will come, says John Stepek. But will …
23 May 2022
Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?
Investment trusts

Scottish Mortgage Investment Trust has fallen hard. But is now the time to buy?

After a spectacular couple of decades, the Scottish Mortgage Investment Trust has fallen by almost 45% so far this year. Rupert Hargreaves asks if no…
26 May 2022
Is it time to pick up growth stock bargains yet?
Investment strategy

Is it time to pick up growth stock bargains yet?

If you’re thinking of picking up some bargains from the tech stock crash, beware – there are still plenty of “growth traps” out there. John Stepek exp…
26 May 2022